Journal of Nuclear Medicine vol:50 issue:5 pages:818-822
We have characterized the biodistribution and dosimetry of F-18-3'-F-6-OH-BTA1 (F-18-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of F-18-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. F-18-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 mu Gy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 mu Sv/MBq, a dose comparable to that of many other F-18-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of F-18-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.